Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study
Lothar Bergmann(Universität Ulm), Michael Staehler(München Klinik), Manfred Kindler(Praxis), Thomas Steiner(Helios Klinikum Erfurt), Michael Scheffler(Westsächsische Hochschule Zwickau), Joerg Schmitz(Springer Nature (Germany)), Ulrich Kube(Goethe Institut), Peter J. Goebell(Friedrich-Alexander-Universität Erlangen-Nürnberg), Edwin Herrmann(St. Jude Children's Research Hospital), Michael Albrecht(Novartis (Germany)), Christian Doehn(University of Lübeck), Steffen Weikert(St. Hedwig-Krankenhaus), Jan Janßen
Cited by 23
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome
|Blood|1997|352
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187
Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
|Clinical Cancer Research|2012|164